Axe Compute

Axe Compute Stock-Based Compensation

The Stock-Based Compensation (SBC) of Axe Compute (AGPU) as of Nov 16, 2026 is 522,437.00 USD. In the previous year, Stock-Based Compensation (SBC) was 921,131.00 USD — a change of -43.28% (lower).

Stock-Based Compensation

522,437.00USD

YoY

-43.28%

Last updated:

Stock-Based Compensation (SBC) of Axe Compute is 2022 522,437.00 USD. Stock-Based Compensation (SBC) of Axe Compute was 2021 921,131.00 USD. It decreases by -43.28% lower compared to the previous year.

The Axe Compute Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2014
835,421.00 USD
Jan 1, 2015
871,877.00 USD
Jan 1, 2016
886,601.00 USD
Jan 1, 2017
4.04 M USD
Jan 1, 2018
1.46 M USD
Jan 1, 2020
1.17 M USD
Jan 1, 2021
921,131.00 USD
Jan 1, 2022
522,437.00 USD
The Axe Compute Stock-Based Compensation history
YEARStock-Based CompensationYoY
522,437.00USD-43.28%
921,131.00USD-21.42%
1.17 MUSD-19.72%
1.46 MUSD-63.88%
4.04 MUSD+355.93%
886,601.00USD+1.69%
871,877.00USD+4.36%
835,421.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Axe Compute Stock analysis

What does Axe Compute do? Predictive Oncology, Inc. generates revenue through its subsidiaries Helomics Holding Corporation and Skyline Medical Inc. Helomics applies artificial intelligence to patient tumor data to personalize cancer therapies and develop new-targeted therapies, offering CLIA-certified clinical testing for oncologists. Skyline Medical Inc. markets the STREAMWAY System, which automates medical fluid disposal, targeting hospitals and clinics globally. The company's products serve healthcare providers seeking advanced diagnostic and waste management solutions. Helomics focuses on personalized cancer treatment decisions using AI-driven analysis, while Skyline Medical Inc. provides automated fluid disposal systems. The STREAMWAY System is sold through domestic and international divisions to medical facilities requiring efficient waste handling. TumorGenesis Inc. supports laboratory-based tumor research, complementing Helomics' clinical offerings. The company's revenue streams include AI-based therapy personalization services and the STREAMWAY System sales. Healthcare providers, including oncologists and medical facilities, purchase these products to enhance treatment precision and operational efficiency. Subsidiaries operate under the parent company's structure, with Helomics handling AI applications and Skyline Medical managing medical device distribution. Axe Compute is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Axe Compute stock

Stock-Based Compensation (SBC) of Axe Compute is 522,437.00 USD in 2022.

Stock-Based Compensation (SBC) of Axe Compute changed from 921,131.00 USD to 522,437.00 USD, representing a -43.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Axe Compute since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Axe Compute historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Axe Compute

All Key Metrics — Axe Compute